Salvage treatment for relapsed/refractory Hodgkin lymphoma: role of allografting, brentuximab vedotin and newer agents

Massimo Martino; Moreno Festuccia; Roberta Fedele; Giuseppe Console; Michele Cimminiello; Paolo Gavarotti; Benedetto Bruno

doi:10.1517/14712598.2015.1130821

Salvage treatment for relapsed/refractory Hodgkin lymphoma: role of allografting, brentuximab vedotin and newer agents

Expert Opinion on Biological Therapy ◽

10.1517/14712598.2015.1130821 ◽

2016 ◽

Vol 16 (3) ◽

pp. 347-364 ◽

Cited By ~ 3

Author(s):

Massimo Martino ◽

Moreno Festuccia ◽

Roberta Fedele ◽

Giuseppe Console ◽

Michele Cimminiello ◽

...

Keyword(s):

Hodgkin Lymphoma ◽

Brentuximab Vedotin ◽

Salvage Treatment ◽

Refractory Hodgkin Lymphoma

Download Full-text

Brentuximab vedotin as a salvage treatment for relapsed and refractory Hodgkin lymphoma patients in Taiwan

Journal of the Formosan Medical Association ◽

10.1016/j.jfma.2019.07.003 ◽

2019 ◽

Vol 118 (10) ◽

pp. 1466-1470 ◽

Cited By ~ 2

Author(s):

Feng-Ming Tien ◽

Cheng-Hong Tsai ◽

Jia-Hau Liu ◽

Chien-Ting Lin

Keyword(s):

Hodgkin Lymphoma ◽

Brentuximab Vedotin ◽

Salvage Treatment ◽

Refractory Hodgkin Lymphoma

Download Full-text

Role of brentuximab vedotin in the treatment of relapsed or refractory Hodgkin lymphoma

Pharmacogenomics and Personalized Medicine ◽

10.2147/pgpm.s57700 ◽

2014 ◽

pp. 79 ◽

Cited By ~ 1

Author(s):

Robert Chen ◽

Tanya Siddiqi ◽

Sandra Thomas

Keyword(s):

Hodgkin Lymphoma ◽

Brentuximab Vedotin ◽

Refractory Hodgkin Lymphoma

Download Full-text

HL-307: A Retrospective Analysis of Brentuximab Vedotin and Pembrolizumab Combination as Salvage Treatment for Patients with Relapsed or Refractory Hodgkin Lymphoma

Clinical Lymphoma Myeloma & Leukemia ◽

10.1016/s2152-2650(20)30845-4 ◽

2020 ◽

Vol 20 ◽

pp. S250

Author(s):

Fulvio Massaro ◽

Marie Maerevoet ◽

Nathalie Meuleman

Keyword(s):

Retrospective Analysis ◽

Hodgkin Lymphoma ◽

Brentuximab Vedotin ◽

Salvage Treatment ◽

Refractory Hodgkin Lymphoma

Download Full-text

BRENTUXIMAB VEDOTIN PLUS BENDAMUSTINE AS FIRST SALVAGE TREATMENT IN PATIENTS WITH RELAPSED OR REFRACTORY HODGKIN LYMPHOMA. EXPERIENCE AT DONOSTIA UNIVERSITY HOSPITAL, SPAIN

Hematological Oncology ◽

10.1002/hon.66_2881 ◽

2021 ◽

Vol 39 (S2) ◽

Author(s):

B. Mendibil Esquisabel ◽

L. Ondarra Segurola ◽

A. Altuna Mongelos ◽

J. Iriondo Alzola ◽

A. Zumalde Murua ◽

...

Keyword(s):

Hodgkin Lymphoma ◽

Brentuximab Vedotin ◽

Salvage Treatment ◽

University Hospital ◽

Refractory Hodgkin Lymphoma

Download Full-text

Comment on “Combining brentuximab vedotin with dexamethasone, high-dose cytarabine and cisplatin as salvage treatment in relapsed or refractory Hodgkin lymphoma: the phase II HOVON/LLPC Transplant BRaVE study.”

Haematologica ◽

10.3324/haematol.2020.278203 ◽

2021 ◽

Vol 106 (4) ◽

pp. 1226-1227

Author(s):

Marco Picardi ◽

Claudia Giordano

Keyword(s):

Hodgkin Lymphoma ◽

Phase Ii ◽

Brentuximab Vedotin ◽

Salvage Treatment ◽

High Dose ◽

High Dose Cytarabine ◽

Refractory Hodgkin Lymphoma

Download Full-text

Brentuximab vedotin in combination with extended field radiotherapy as salvage treatment for primary refractory Hodgkin lymphoma

American Journal of Hematology ◽

10.1002/ajh.23925 ◽

2015 ◽

Vol 90 (4) ◽

pp. E73-E73 ◽

Cited By ~ 5

Author(s):

Massimo Dozzo ◽

Francesco Zaja ◽

Stefano Volpetti ◽

Alessandra Sperotto ◽

Alessandro Magli ◽

...

Keyword(s):

Hodgkin Lymphoma ◽

Brentuximab Vedotin ◽

Salvage Treatment ◽

Extended Field ◽

Refractory Hodgkin Lymphoma

Download Full-text

Combining brentuximab vedotin with dexamethasone, high-dose cytarabine and cisplatin as salvage treatment in relapsed or refractory Hodgkin lymphoma: the phase II HOVON/LLPC Transplant BRaVE study

Haematologica ◽

10.3324/haematol.2019.243238 ◽

2020 ◽

pp. haematol.2019.243238 ◽

Cited By ~ 1

Author(s):

Marie José Kersten ◽

Julia Driessen ◽

Josée M. Zijlstra ◽

Wouter J. Plattel ◽

Franck Morschhauser ◽

...

Keyword(s):

Hodgkin Lymphoma ◽

Phase Ii ◽

Brentuximab Vedotin ◽

Salvage Treatment ◽

High Dose ◽

High Dose Cytarabine ◽

Refractory Hodgkin Lymphoma

Download Full-text

Experience of brentuximab vedotin in relapsed/refractory Hodgkin lymphoma and relapsed/refractory systemic anaplastic large-cell lymphoma in the Named Patient Program: Review of the literature

Critical Reviews in Oncology/Hematology ◽

10.1016/j.critrevonc.2015.03.011 ◽

2015 ◽

Vol 95 (3) ◽

pp. 359-369 ◽

Cited By ~ 19

Author(s):

P.L. Zinzani ◽

S. Sasse ◽

J. Radford ◽

O. Shonukan ◽

V. Bonthapally

Keyword(s):

Hodgkin Lymphoma ◽

Anaplastic Large Cell Lymphoma ◽

Cell Lymphoma ◽

Large Cell ◽

Brentuximab Vedotin ◽

Program Review ◽

Review Of The Literature ◽

Large Cell Lymphoma ◽

Refractory Hodgkin Lymphoma

Download Full-text

Autologous stem-cell transplantation after second-line brentuximab vedotin in relapsed or refractory Hodgkin lymphoma

Annals of Oncology ◽

10.1093/annonc/mdx791 ◽

2018 ◽

Vol 29 (3) ◽

pp. 724-730 ◽

Cited By ~ 11

Author(s):

A.F. Herrera ◽

J. Palmer ◽

P. Martin ◽

S. Armenian ◽

N.-C. Tsai ◽

...

Keyword(s):

Stem Cell ◽

Stem Cell Transplantation ◽

Hodgkin Lymphoma ◽

Cell Transplantation ◽

Autologous Stem Cell Transplantation ◽

Brentuximab Vedotin ◽

Second Line ◽

Refractory Hodgkin Lymphoma

Download Full-text

Treatment patterns and costs of care for patients with relapsed and refractory Hodgkin lymphoma treated with brentuximab vedotin in the United States: A retrospective cohort study

PLoS ONE ◽

10.1371/journal.pone.0180261 ◽

2017 ◽

Vol 12 (10) ◽

pp. e0180261 ◽

Cited By ~ 7

Author(s):

Shelagh M. Szabo ◽

Ishan Hirji ◽

Karissa M. Johnston ◽

Ariadna Juarez-Garcia ◽

Joseph M. Connors

Keyword(s):

United States ◽

Cohort Study ◽

Hodgkin Lymphoma ◽

Retrospective Cohort Study ◽

Retrospective Cohort ◽

The United States ◽

Brentuximab Vedotin ◽

Treatment Patterns ◽

Costs Of Care ◽

Refractory Hodgkin Lymphoma

Download Full-text